HARP News

In the second week after the SEC opened we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP), along with three SPACs, also priced their IPOS. Alector, a Phase 1 biotech developing therapies for...read more

Harpoon Therapeutics, a Phase 1 biotech developing T cell immunotherapies for various cancers, raised $76 million by offering 5.4 million shares at $14, the midpoint of the  $13 to $15 range. Harpoon Therapeutics plans to list on the Nasdaq under the symbol HARP. Citi and SVB Leerink acted as lead managers on the deal....read more

Four IPOs plan to raise $523 million in the week ahead. Biotechs are still a strong force in the IPO market with three early-stage immunotherapy plays on the docket, including two with proposed billion-dollar valuations. A micro-cap Florida bank rounds out the group. Two blank check companies are also on the week's ...read more

Harpoon Therapeutics, a Phase 1 biotech developing immunotherapies for various cancers, announced terms for its IPO on Tuesday. The South San Francisco, CA-based company plans to raise $76 million by offering 5.4 million shares at a price range of $13 to $15. Insiders intend to purchase $40 million worth of shares in the offering (53% of the deal). At the midpoint of the...read more